The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and mitigate supply chain vulnerabilities, including collaborating with the private sector to develop and implement programs to assess and incentivize resiliency in manufacturer and hospital purchasing behavior. The paper focuses on generic sterile injectable medicines used in inpatient settings, citing their importance and relative risk of supply disruptions.

Related News Articles

Headline
The AHA urged the Department of Commerce Oct. 17 to take a balanced approach to ensuring dependable and affordable access to personal protective equipment,…
Headline
The AHA’s Association for Health Care Resource & Materials Management has created a webpage featuring resources on tariffs impacting the health care supply…
Headline
The AHA provided a statement of record to the Senate Special Committee on Aging for a hearing Oct. 8 on the pharmaceutical and medical device supply chains.…
Headline
President Trump, late Sept. 25, announced that starting Oct. 1, the U.S. will impose a 100% tariff on any branded or patented pharmaceutical product, unless a…
Headline
The Department of Commerce Sept. 24 released a notice seeking public comment on an investigation it launched Sept. 2 on imports of personal protective…
Headline
The Food and Drug Administration has identified a Class I recall of certain Olympus ViziShot 2 FLEX Needles due to a possible patient safety issue caused by a…